Patients with statin intolerance had a 36% higher rate of recurrent MI compared to those with high statin adherence.
Women experienced the same CV benefits in statin trials, despite having slightly elevated on-treatment LDL cholesterol.
Risk of both ischemic stroke and coronary heart disease was elevated with high triglycerides and low high-density lipoprotein cholesterol.
Low levels of low-density lipoprotein cholesterol appear to be well tolerated on alirocumab therapy.
Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.
Too few American young adults are receiving needed statin medications, according to findings published in JAMA Cardiology.
Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.
Oxidized low-density lipoprotein (ox-LDL) as a proxy for oxidative stress is associated with metabolic syndrome and its components.
Healthier diets may be a factor in the ongoing decline in cholesterol levels for Americans.
Women and minorities with HIV are less frequently tested for dyslipidemia, according to a new study from IDWeek 2016.
Endocrinology Advisor Articles
- Maternal Deaths in the United States: Sounding a Call to Action
- Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes
- Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control
- Major Cardiovascular Event Incidence in T2D: Degludec vs Glargine
- The Handoff: Your Week in Endocrinology News - 6/23/17
- Reduced Cardiovascular Events in Type 2 Diabetes Treated With Dapagliflozin
- Canagliflozin Reduces Cardiovascular Stress In Older Patients With Type 2 Diabetes
- Diabetic Retinopathy Caused by Sleep Apnea in T2D
- Transition-of-Care Algorithm Performs Well in Surgery Patients With Type 2 Diabetes
- GLP-1 Analog Counteracts Antipsychotic-Induced Glucose Intolerance, Weight Gain